References
- Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;228:321–33
- Khastgir G, Studd JWW, Holland N, et al. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab 2001;86:289–95
- Khastgir G, Studd J, Holland N, et al. Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporosis Int 2001;12:465–70
- Muscat Baron Y, Brincat MP, Galea R, Callega N. Low intervertebral disc height in postmenopausal women with osteoporotic vertebral fractures compared to hormone-treated and untreated postmenopausal women and premenopausal women without fractures. Climacteric 2007;10:314–19
- Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
- Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trail. JAMA 2004;291:1701–12
- Studd JWW. Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. Climacteric 2009;12:206–9
- Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346–50
- Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;341:c4444
- Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319–26
- Bagger YZ, Tanko LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women has long term preventative effects on bone mass and osteoporotic fracture: the PERF study. Bone 2004;34:728–35
- Soares CN, Almeida, Joff H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58:529–34
- Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal estrogen for the treatment of severe post-natal depression. Lancet 1996;347:930–3
- Watson NR, Studd JW, Savvas M, Garnett T, Baber RJ. Treatment of severe premenstrual syndrome with estradiol patches and cyclical oral norethisterone. Lancet 1989;2:730–2
- Studd J, Panay N. Hormones and depression in women. Climacteric 2004;7:338–46
- Mojtabai R. Increase in antidepressant medication in the US adult population between 1990 and 2003. Psychother Psychosom 2008;77:83–92
- Smoller JW, Allison M, Cochrane BB, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch Intern Med 2009;169:2128–39
- Studd JW. Why are estrogens rarely used for the treatment of depression in women? Gynecol Endocrinol 2007;23:63–4
- Carroll DG, Kelley KW. Use of antidepressants for management of hot flushes. Pharmacotherapy 2009;29:1357–74